Tetra Bio Pharma Inc
TSX:TBP

Watchlist Manager
Tetra Bio Pharma Inc Logo
Tetra Bio Pharma Inc
TSX:TBP
Watchlist
Price: 0.025 CAD Market Closed
Market Cap: 10.6m CAD

Tetra Bio Pharma Inc
Change in Deffered Taxes

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Tetra Bio Pharma Inc
Change in Deffered Taxes Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Change in Deffered Taxes CAGR 3Y CAGR 5Y CAGR 10Y
Tetra Bio Pharma Inc
TSX:TBP
Change in Deffered Taxes
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bausch Health Companies Inc
TSX:BHC
Change in Deffered Taxes
$95m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Canopy Growth Corp
TSX:WEED
Change in Deffered Taxes
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Sundial Growers Inc
NASDAQ:SNDL
Change in Deffered Taxes
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cronos Group Inc
TSX:CRON
Change in Deffered Taxes
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
K
Knight Therapeutics Inc
TSX:GUD
Change in Deffered Taxes
-CA$5.4m
CAGR 3-Years
23%
CAGR 5-Years
-5%
CAGR 10-Years
N/A
No Stocks Found

Tetra Bio Pharma Inc
Glance View

Market Cap
10.6m CAD
Industry
Pharmaceuticals

Tetra Bio-Pharma, Inc. engages in the discovery and development of cannabinoid-based drugs and treatments. The company is headquartered in Orleans, Ontario and currently employs 33 full-time employees. The company went IPO on 2008-04-15. The firm is engaged in the development of bio pharmaceuticals and natural health products containing cannabis and other medicinal plant-based elements. The firm is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. The firm's objective is to bring prescription drugs and treatments to relieve symptoms associated with advanced cancer pain, chronic pain, Acute Respiratory Distress Syndrom (ARDS), sepsis and ophthalmic disease. Its products include QIXLEEF, CAUMZ, REDUVO Capsules, REDUVO Adversa, ARDS-003 and PPP-002. Its QIXLEEF is a botanical inhaled drug with a fixed ratio of tetrahydrocannabinol (THC) and cannabidiol (CBD).

TBP Intrinsic Value
Not Available

See Also

Back to Top